Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Research to Improve the Detection and Treatment of Latent Tuberculosis Infection: Diagnostics (RID-TB:Dx)
2019-002592-34Phase 3Unknown
- Sponsor
- University College London
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of C-Tb in latent tuberculosis infection (LTBI) (2 arms), sponsored by University College London. Primary endpoint: Proportion of participants with positive test results who initiate LTBI treatment. Status: unknown.
02
Drugs
C-Tb
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2019-002592-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002592-34.